Filing Flows › Mirum Pharmaceuticals (MIRM) › Stock forecast & fair value
Mirum Pharmaceuticals (MIRM) stock forecast and price target
Mirum Pharmaceuticals (MIRM) trades at $93.72. 14 analysts' median price target is $153.50 (+64%), from $118.00 to $200.00.
Mirum Pharmaceuticals' latest quarter
Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for MIRM stock?
The median of 14 analysts' 12-month targets is $153.50, +64% from $93.72; the range is $118.00 to $200.00. The average rating is strong buy.
Does Mirum Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 20% of the quarters on record.
Is MIRM stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.